KEAP1 and non-small cell lung carcinoma: Meanwhile, KEAP1 mutation was a therapeutic target for Telaglenastat, the new targeted drug for NSCLC, which was expected to bring new hope to more than 20% of patients with NSCLC (Riess et al., 2021).